MTVA - MetaVia Inc. Stock Analysis

Stock Taper

SCREENER COMPARE ANY 2 STOCKS

MTVA

METAVIA INC.

NASDAQ

$1.70

▲ UP 2.41% (0.04)

KEY STATISTICS

Market Cap$3.74 M

52w High$19.03

52w Low$0.97

Dividend Yield—

Frequency—

P/E-1.08

Volume36.57K

Shares Out.2.20M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Hyung Heon Kim

ABOUT

SECTOR

Healthcare

WENT PUBLIC

August 5, 2016

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateNov 5, 2026

DayThursday

Rev. Est.—

NOV

THU

SPLIT RECORD

DATE	TYPE	RATIO
2025-12-05	Reverse	1:11
2023-12-21	Reverse	1:8
2022-09-13	Reverse	1:30
2019-12-31	Reverse	1:25

PRICE

$1.70 ▲ UP 2.41% (+$0.04)

OVERLAYS

About MetaVia Inc.

https://www.metaviatx.com ↗

MetaVia Inc. is a Cambridge-based biotech developing novel therapies for cardiometabolic diseases, including Phase 2a drug DA-1241 for MASH and preclinical DA-1726 for obesity, with additional programs targeting COVID-19, neuropathy, cognitive imp...

INDUSTRY

Biotechnology

A PRODUCT METAVIA INC. IS KNOWN FOR

DA-1726

DA-1726, a clinical-stage dual GLP1R and GCGR agonist developed by MetaVia, aims to treat obesity by reducing appetite and boosting energy expenditure, showing best-in-class potential in Phase 1 trials within the cardiometabolic sector.